Is LUV Stock a Buy, Sell or Hold?
Southwest Airlines (NYSE:LUV) is one of America’s major air transportation…
Sell
34
SWTX Quote, Financials, Valuation and Earnings
Last price:
$46.55
Seasonality move
:
-1.61%
Day range:
$41.30 - $46.95
52-week range:
$28.21 - $62.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.00x
P/B ratio:
7.25x
Volume:
4.6M
Avg. volume:
2.4M
1-year change:
0.5%
Market cap:
$3.5B
Revenue:
$191.6M
EPS (TTM):
-$3.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$66.9M | -$0.74 | 218.64% | -37.01% | $72.88 |
|
ACAD
ACADIA Pharmaceuticals
|
$239.3M | -$0.03 | 16.28% | -91.94% | $24.85 |
|
ADMA
ADMA Biologics
|
$116.4M | $0.14 | 42.17% | 75% | $25.27 |
|
AXSM
Axsome Therapeutics
|
$121.6M | -$1.29 | 61.86% | -6.01% | $172.47 |
|
GRCE
Grace Therapeutics
|
-- | -$0.24 | -- | -63.24% | $11.88 |
|
INSM
Insmed
|
$91.6M | -$1.36 | 21.36% | -28.6% | $95.78 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$46.52 | $72.88 | $3.5B | -- | $0.00 | 0% | 18.00x |
|
ACAD
ACADIA Pharmaceuticals
|
$16.62 | $24.85 | $2.8B | 12.22x | $0.00 | 0% | 2.89x |
|
ADMA
ADMA Biologics
|
$20.23 | $25.27 | $4.8B | 24.67x | $0.00 | 0% | 11.52x |
|
AXSM
Axsome Therapeutics
|
$109.75 | $172.47 | $5.4B | -- | $0.00 | 0% | 13.63x |
|
GRCE
Grace Therapeutics
|
$2.31 | $11.88 | $31.7M | -- | $0.00 | 0% | -- |
|
INSM
Insmed
|
$73.44 | $95.78 | $13.3B | -- | $0.00 | 0% | 33.12x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
-- | 1.659 | -- | 3.54x |
|
ACAD
ACADIA Pharmaceuticals
|
-- | 0.878 | -- | 2.18x |
|
ADMA
ADMA Biologics
|
17.17% | 2.782 | 1.78% | 2.76x |
|
AXSM
Axsome Therapeutics
|
76.02% | 1.663 | 4.39% | 1.99x |
|
GRCE
Grace Therapeutics
|
-- | 1.718 | -- | -- |
|
INSM
Insmed
|
79.45% | 5.493 | 8.91% | 4.99x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SWTX
SpringWorks Therapeutics
|
$56M | -$81.3M | -46.69% | -46.69% | -132.16% | -$35.6M |
|
ACAD
ACADIA Pharmaceuticals
|
$237.8M | $7M | 41.59% | 41.59% | 2.69% | $39.9M |
|
ADMA
ADMA Biologics
|
$63.3M | $38.3M | 60.85% | 93.41% | 31.98% | $47.5M |
|
AXSM
Axsome Therapeutics
|
$108.3M | -$61.6M | -96.73% | -244.32% | -61.14% | -$26.2M |
|
GRCE
Grace Therapeutics
|
-- | -$3.7M | -- | -- | -- | -$4.1M |
|
INSM
Insmed
|
$78.3M | -$245.2M | -82.19% | -41989.34% | -205.36% | -$202.8M |
SpringWorks Therapeutics vs. Competitors
-
Which has Higher Returns SWTX or ACAD?
ACADIA Pharmaceuticals has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 55.37%. SpringWorks Therapeutics's return on equity of -46.69% beat ACADIA Pharmaceuticals's return on equity of 41.59%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M ACADACADIA Pharmaceuticals91.6% $0.86 $732.8M -
What do Analysts Say About SWTX or ACAD?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 56.65%. On the other hand ACADIA Pharmaceuticals has an analysts' consensus of $24.85 which suggests that it could grow by 49.52%. Given that SpringWorks Therapeutics has higher upside potential than ACADIA Pharmaceuticals, analysts believe SpringWorks Therapeutics is more attractive than ACADIA Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 ACADACADIA Pharmaceuticals6 7 0 -
Is SWTX or ACAD More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals has a beta of 0.537, suggesting its less volatile than the S&P 500 by 46.313%.
-
Which is a Better Dividend Stock SWTX or ACAD?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ACADIA Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or ACAD?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ACADIA Pharmaceuticals quarterly revenues of $259.6M. SpringWorks Therapeutics's net income of -$77.3M is lower than ACADIA Pharmaceuticals's net income of $143.7M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ACADIA Pharmaceuticals's PE ratio is 12.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.00x versus 2.89x for ACADIA Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics18.00x -- $61.5M -$77.3M ACADACADIA Pharmaceuticals2.89x 12.22x $259.6M $143.7M
-
Which has Higher Returns SWTX or ADMA?
ADMA Biologics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of 95.19%. SpringWorks Therapeutics's return on equity of -46.69% beat ADMA Biologics's return on equity of 93.41%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M ADMAADMA Biologics53.88% $0.46 $421.4M -
What do Analysts Say About SWTX or ADMA?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 56.65%. On the other hand ADMA Biologics has an analysts' consensus of $25.27 which suggests that it could grow by 24.93%. Given that SpringWorks Therapeutics has higher upside potential than ADMA Biologics, analysts believe SpringWorks Therapeutics is more attractive than ADMA Biologics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 ADMAADMA Biologics4 0 0 -
Is SWTX or ADMA More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.527, suggesting its less volatile than the S&P 500 by 47.277%.
-
Which is a Better Dividend Stock SWTX or ADMA?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or ADMA?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than ADMA Biologics quarterly revenues of $117.5M. SpringWorks Therapeutics's net income of -$77.3M is lower than ADMA Biologics's net income of $111.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while ADMA Biologics's PE ratio is 24.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.00x versus 11.52x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics18.00x -- $61.5M -$77.3M ADMAADMA Biologics11.52x 24.67x $117.5M $111.9M
-
Which has Higher Returns SWTX or AXSM?
Axsome Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -63.08%. SpringWorks Therapeutics's return on equity of -46.69% beat Axsome Therapeutics's return on equity of -244.32%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M AXSMAxsome Therapeutics91.15% -$1.54 $237.7M -
What do Analysts Say About SWTX or AXSM?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 56.65%. On the other hand Axsome Therapeutics has an analysts' consensus of $172.47 which suggests that it could grow by 57.15%. Given that Axsome Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Axsome Therapeutics is more attractive than SpringWorks Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 AXSMAxsome Therapeutics12 0 0 -
Is SWTX or AXSM More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.883, suggesting its less volatile than the S&P 500 by 11.73%.
-
Which is a Better Dividend Stock SWTX or AXSM?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or AXSM?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Axsome Therapeutics quarterly revenues of $118.8M. SpringWorks Therapeutics's net income of -$77.3M is lower than Axsome Therapeutics's net income of -$74.9M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.00x versus 13.63x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics18.00x -- $61.5M -$77.3M AXSMAxsome Therapeutics13.63x -- $118.8M -$74.9M
-
Which has Higher Returns SWTX or GRCE?
Grace Therapeutics has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of --. SpringWorks Therapeutics's return on equity of -46.69% beat Grace Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M GRCEGrace Therapeutics-- -$0.36 -- -
What do Analysts Say About SWTX or GRCE?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 56.65%. On the other hand Grace Therapeutics has an analysts' consensus of $11.88 which suggests that it could grow by 414.2%. Given that Grace Therapeutics has higher upside potential than SpringWorks Therapeutics, analysts believe Grace Therapeutics is more attractive than SpringWorks Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 GRCEGrace Therapeutics1 0 0 -
Is SWTX or GRCE More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Grace Therapeutics has a beta of 1.327, suggesting its more volatile than the S&P 500 by 32.655%.
-
Which is a Better Dividend Stock SWTX or GRCE?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grace Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Grace Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or GRCE?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are larger than Grace Therapeutics quarterly revenues of --. SpringWorks Therapeutics's net income of -$77.3M is lower than Grace Therapeutics's net income of -$4.2M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Grace Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.00x versus -- for Grace Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics18.00x -- $61.5M -$77.3M GRCEGrace Therapeutics-- -- -- -$4.2M
-
Which has Higher Returns SWTX or INSM?
Insmed has a net margin of -125.59% compared to SpringWorks Therapeutics's net margin of -225.53%. SpringWorks Therapeutics's return on equity of -46.69% beat Insmed's return on equity of -41989.34%.
Company Gross Margin Earnings Per Share Invested Capital SWTXSpringWorks Therapeutics90.98% -$1.04 $481.1M INSMInsmed74.96% -$1.32 $1.4B -
What do Analysts Say About SWTX or INSM?
SpringWorks Therapeutics has a consensus price target of $72.88, signalling upside risk potential of 56.65%. On the other hand Insmed has an analysts' consensus of $95.78 which suggests that it could grow by 30.02%. Given that SpringWorks Therapeutics has higher upside potential than Insmed, analysts believe SpringWorks Therapeutics is more attractive than Insmed.
Company Buy Ratings Hold Ratings Sell Ratings SWTXSpringWorks Therapeutics5 0 0 INSMInsmed12 0 0 -
Is SWTX or INSM More Risky?
SpringWorks Therapeutics has a beta of 0.787, which suggesting that the stock is 21.261% less volatile than S&P 500. In comparison Insmed has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.18%.
-
Which is a Better Dividend Stock SWTX or INSM?
SpringWorks Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SpringWorks Therapeutics pays -- of its earnings as a dividend. Insmed pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios SWTX or INSM?
SpringWorks Therapeutics quarterly revenues are $61.5M, which are smaller than Insmed quarterly revenues of $104.4M. SpringWorks Therapeutics's net income of -$77.3M is higher than Insmed's net income of -$235.5M. Notably, SpringWorks Therapeutics's price-to-earnings ratio is -- while Insmed's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SpringWorks Therapeutics is 18.00x versus 33.12x for Insmed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SWTXSpringWorks Therapeutics18.00x -- $61.5M -$77.3M INSMInsmed33.12x -- $104.4M -$235.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
54
NUTX alert for Apr 3
Nutex Health [NUTX] is up 5.41% over the past day.
Sell
50
PVH alert for Apr 3
PVH [PVH] is up 1.81% over the past day.
Sell
15
PCVX alert for Apr 3
Vaxcyte [PCVX] is up 4.47% over the past day.
